Ferroptosis-related gene signature predicts the prognosis in Oral squamous cell carcinoma patients

Abstract

Background The prognosis of oral squamous cell carcinoma (OSCC) patients is difficult to predict or describe due to its high-level heterogeneity and complex aetiologic factors. Ferroptosis is a novel form of iron-dependent cell death that is closely related to tumour growth and progression. This study aims to clarify the predictive value of ferroptosis-related genes (FRGs) on the overall survival(OS) of OSCC patients. Methods The mRNA expression profile of FRGs and clinical information of patients with OSCC were collected from the TCGA database. Candidate differentially expressed ferroptosis-related genes (DE-FRGs) were identified by analysing differences between OSCC and adjacent normal tissues. A gene signature of prognosis-related DE-FRGs was established by univariate Cox analysis and LASSO analysis in the training set. Patients were then divided into high- and low-risk groups according to the cut-off value of risk scores, A nomogram was constructed to quantify the contributions of gene signature and clinical parameters to OS. Then several bioinformatics analyses were used to verify the reliability and accuracy of the model in the validation set. Finally, single-sample gene set enrichment analysis (ssGSEA) was also performed to reveal the underlying differences in immune status between different risk groups. Results A prognostic model was constructed based on 10 ferroptosis-related genes. Patients in high-risk group had a significantly worse OS (p < 0.001). The gene signature was verified as an independent predictor for the OS of OSCC patients (HR > 1, p < 0.001). The receiver operating characteristic curve displayed the favour predictive performance of the risk model. The prediction nomogram successfully quantified each indicator’s contribution to survival and the concordance index and calibration plots showed its superior predictive capacity. Finally, ssGSEA preliminarily indicated that the poor prognosis in the high-risk group might result from the dysregulation of immune status. Conclusion This study established a 10-ferroptosis-releated gene signature and nomogram that can be used to predict the prognosis of OSCC patients, which provides new insight for future anticancer therapies based on potential FRG targets.

In vivo Safety and Immunoactivity of Oncolytic Jurona Virus in Hepatocellular Carcinoma: A Comprehensive Proteogenomic Analysis

“…A comparison of DEPs/DEGs illustrates that most up-regulated features, including Anxa3 74 , Hspg2 75 , Cyp2e1 76 and Map1lc3a 77 are therapeutic targets in immunotherapy or function as tumor suppressor genes (Fig. 6 e).…”

“…Hspg275 , Cyp2e176 and Map1lc3a77 are therapeutic targets in immunotherapy or function as tumor suppressor genes ( Fig.6 e). In addition, to assess the relationship between the local and systemic anti-tumor immunity in the murine tumors, we performed Go term enrichment analysis of DEGs between the JURV-injected and non-injected HEPA 1-6 tumors.…”

Association between cancer stem cell gene expression signatures and prognosis in head and neck squamous cell carcinoma

“…High expression of these genes is associated with poor prognosis in HNSCC [ 41 – 43 ]. Hypoxia- and ferroptosis-related gene signatures predicting the prognosis of patients with OSCC have also been identified and validated [ 44 , 45 ]. In this study, we developed and validated signatures associated with CSC biomarker genes, the expression of which was correlated with the prognosis of patients with HNSCC.…”

NCBP2 and TFRC are Novel Prognostic Biomarkers in Oral Squamous Cell Carcinoma

“…DAB-based IHC staining is a cost-effective and commonly used tool in pathology. Therefore, our DAB IHC-based assay offers a clinically feasible way to measure biomarker expression in OSCC patients that is less complex than assessing multigene prognostic signatures (39). These novel biomarkers may provide an additional prognostic tool to clinicians beside currently used tumour staging approaches, allowing for more informed treatment decisions.…”